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A B S T R A C T
With perioperative pain control it is possible to supervise immune system, release of inflammation mediators, and in-
fluence on treatment outcome. Use of analgetics before the pain stimulus (preventive analgesia) obstruct development of
neuroplastic changes in central nervous system, and reduces pain. Investigation hypothesis was that preoperative epi-
dural clonidine is more efficient in blockade of systemic inflammatory stress response comparing to levobupivacaine. Pa-
tients were allocated to three groups, according to preoperative epidural use of clonidine, levobupivacaine or saline (con-
trol group). Before operation, 1 h after the beginning, 1 h, 6 h, 12 h and 24 h after the operation following parameters
were analyzed: interleukine-6, C-reactive protein and leukocyte count. There were no significant differences between
groups in age, gender, body mass index and operation time. In preoperative clonidine group, we found significant reduc-
tion in interleukine-6 levels throughout investigation time, compared to preoperative levobupivacaine group and control
group. Also, C-reactive protein was significantly lower at the end of investigation, compared to other two groups. Leuko-
cyte count was lower, and within the normal range in all investigation times only in preoperative clonidine group. We
demonstrated significant difference that support importance of clonidine central effect on pain pathways and systemic
inflammatory blockade.
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Introduction
Postoperative period is associated with an increased
production of cytokines, which augment pain sensitivity.
Use of analgesics for immunomodulation can improve
patient recovery1.
Preventive analgesia is based on the concept that the
occurrence of strong pain stimulus, hyperexcitation and
hyperalgesia are possible to prevent by early blockade of
pain pathways2,3. Prolonged pain stimulus leads to sec-
ondary neuroplastic changes in the central nervous sys-
tem, known as central sensitization, resulting in exag-
gerated response to afferent pain stimulus and amplifica-
tion of pain (hyperalgesia). Administration of analgesics
before the pain stimulus or surgical trauma, prevents
harmful central nervous system response and inflamma-
tion as an early consequence of operation as well. In or-
der to achieve success, preventive analgesia should meet
two important conditions, i.e. complete suppression of
the afferent pain stimulus and adequate duration in the
early postoperative course4,5.
Clonidine is an a2-adrenergic agonist with sedative,
analgesic and hemodynamic properties. It inhibits trans-
mission of nociceptive stimuli in the dorsal horn of the
spinal cord, acting on the inhibitory descending path-
ways. According to recent investigations clonidine lowers
proinflammatory cytokine level, and prevents hypersen-
sitization acting through adrenoreceptors alpha-2A6. In-
vestigation of Wu et al. reported reduced postoperative
pain level, analgesics consumption and IL-1RA, IL-6 and
IL-8 levels during and after operation, associated with
preoperative epidural clonidine treatment7. This results
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contribute to clonidine attenuating systemic inflamma-
tory stress response. According to Nader et al. preopera-
tive administration of clonidine reduced TNF-alpha level
in plasma and cerebrospinal fluid8. Preoperative epidural
clonidine was superior to intravenous route in postopera-
tive pain control and immune stress response blockade in
investigation of Novak-Jankovic et al., which benefit to
his central effect9.
Levobupivacaine is novel long-acting local anesthetic,
S-enantiomer of bupivacaine, with identical anesthetic
potency12,13. When administered intraperitonealy or by
local infiltration of operation site, levobupivacaine pro-
duced analgesia and reduction of proinflammatory cyto-
kines14–16. Investigations of epidural and intrathecal levo-
bupivacaine provide evidence for improved postoperative
analgesia with reduced analgesic consumption18,19. But,
it remains unknown if that analgesia is sufficient enough
to blockade inflammatory stress response during perio-
perative time.
The aim of the present study was to investigate hy-
pothesis that preoperative administration of epidural
clonidine is more efficient in systemic inflammatory stress
response blockade than epidural levobupivacaine. The
study was designed to compare clonidine and levobupi-
vacaine, and than both with the control group.
Materials and Methods
The investigation was carried out in the double-blin-
ded manner, with due approval from the institution Eth-
ics Committee and an informed consent from all study
subjects. The study included 42 patients undergoing co-
lorectal resection surgery. According to the perioperative
risk of anesthesia and operation, study patients were
classified as ASA (American Society of Anesthesiologists)
physical status I or II. Exclusion criteria were diabetes
mellitus, renal and liver insufficiency, autoimmune dis-
ease, corticosteroid and immunosupressive use, and op-
eration time exceeding six hours.
Patients were randomized into three groups: preoper-
ative epidural clonidine (Group 1), preoperative epidural
levobupivacaine (Group 2) and preoperative epidural sa-
line as a control group (Group 3). On the day before the
operation, patients were informed on the perioperative
procedure, especially of introducing an epidural catheter
for pain therapy. Before the operation, a epidural cathe-
ter was inserted at the Th10-L1 level (BRAUN Perifix 20
G catheter, winged 18 G Tuohy needle). Correct position-
ing was tested using 2 mL 2% lidocaine. Patient was ob-
served for 5 minutes for the development of sensory
blockade changes.
One hour prior to skin incision patients received 5
mg/kg of clonidine (Catapres®, Boehringer Ingelheim), 7
mL of 0.25% levobupivacaine (Chirocaine®, Abbott S.p.A.)
or saline. The operation was performed under general
anesthesia using midazolam (0.15 mg/kg), fentanyl (2
mg/kg) and vecuronium (0.1 mg/kg) to facilitate endo-
tracheal intubation, and sevoflurane, nitrous oxide 50%
in oxygen, boluses of fentanyl and vecuronium for main-
tenance. After the surgery and recovery from anesthesia,
patients were transferred to intensive care unit for con-
tinuous monitoring of vital functions and homeostasis.
On their demand, upon the pain complaint all patients
received boluses of epidural morphine 0.06 mg/kg diluted
in 20 mL of isotonic saline.
Before operation (T0), 1 h after the beginning (T1), 1
h (T2), 6 h (T3), 12 h (T4) and 24 h (T5) after the opera-
tion following parameters were analyzed: interleuki-
ne-6 (IL-6), C-reactive protein (CRP) and leukocyte
count (L).
Statistical analysis was performed using the one-way
analysis of variance (ANOVA). Statistical significance
was set at p<0.05. Results were expressed as Mean ± SD.
Results
There were no significant age, gender and body mass
index differences among the groups of patients relative
to pharmacokinetic and pharmacodynamic drug patern.
Duration of operations were similar. In the preoperative
clonidine group, we found significant reduction in IL-6
levels throughout investigation time, compared to pre-
operative levobupivacaine group and control group of
patients (Table 1). Statistical differences were comfirmed
at investigation times T1, T2, T3, T4 and T5 (Table 2).
CRP was significantly lower at the end of investiga-
tion, compared to other two groups (Table 3). Statistical
difference was found in T5 (Table 4). Also, in preopera-
tive clonidine group leukocyte count was lower, and
within the normal range in all investigation times, com-
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TABLE 1
INTERLEUKINE-6 LEVELS
GROUP Mean SD
Group 1 IL-6 (pg/mL) /T0
IL-6 (pg/mL) /T1
IL-6 (pg/mL) /T2
IL-6 (pg/mL) /T3
IL-6 (pg/mL) /T4
IL-6 (pg/mL) /T5
0.05
0.394
8.941
18.865
16.571
12.512
0.123
0.8105
2.3369
3.3339
3.6107
4.9777
Group 2 IL-6 (pg/mL) /T0
IL-6 (pg/mL) /T1
IL-6 (pg/mL) /T2
IL-6 (pg/mL) /T3
IL-6 (pg/mL) /T4
IL-6 (pg/mL) /T5
0.36
2.092
20.817
39.167
29.817
23.342
1.026
2.7064
13.9161
13.1461
11.5760
12.5872
Group 3 IL-6 (pg/mL) /T0
IL-6 (pg/mL) /T1
IL-6 (pg/mL) /T2
IL-6 (pg/mL) /T3
IL-6 (pg/mL) /T4
IL-6 (pg/mL) /T5
0.38
2.546
55.277
79.623
71.985
57.715
0.985
2.7440
16.4381
12.0297
11.2838
16.3108
pared to other two groups (Table 5). Statistical differences
were found at T2, T3, T4 and T5 (Table 6).
Discussion
Patients undergoing major surgical resection for can-
cer are at high risk for postoperative infectious complica-
tions, due to excessive inflammatory stres response on
surgery and anesthesia. They may benefit from early and
efficient perioperative analgesia, in order to attenuate
this response. Studies of preoperative analgesia in major
colorectal surgery patients were predominantly investi-
gating postoperative pain level and analgesics consump-
tion. Therefore, it is not known if analgesic potency is
sufficient for inflammatory response blockade. Clonidine
was usually used alone, or in combination with local an-
esthetics and opioids. Several attempts have been made
to compare epidural and systemic administration of clo-
nidine. Compared to intravenous administration, epi-
dural clonidine seems to be more potent20. Reduction in
the clonidine requirement when administered by epi-
dural route provided indirect evidence for the main site
of its analgesic action.
In our study, clonidine was administered by epidural
route in dose of 5 mg/kg. We found that IL-6 level in-
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TABLE 2
DIFFERENCE IN INTERLEUKINE-6 LEVELS
Sum of
Squares
df Mean Square F Sig.
IL-6 /T0
Between Groups
Within Groups
Total
1.034
23.468
24.503
2
39
41
0.517
0.602
0.859 0.431
IL-6 /T1
Between Groups
Within Groups
Total
39.133
181.431
220.564
2
39
41
19.567
4.652
4.206 0.022
IL-6 /T2
Between Groups
Within Groups
Total
16393.055
5460.141
21853.196
2
39
41
8196.528
140.004
58.545 0.000
IL-6 /T3
Between Groups
Within Groups
Total
27505.957
3815.429
31321.386
2
39
41
13752.979
97.832
140.578 0.000
IL-6 /T4
Between Groups
Within Groups
Total
23614.539
3210.529
26825.068
2
39
41
11807.269
82.321
143.429 0.000
IL-6 /T5
Between Groups
Within Groups
Total
15710.306
5331.764
21042.070
2
39
41
7855.153
136.712
57.458 0.000
*P<0.05
TABLE 3
C-REACTIVE PROTEIN LEVEL
GROUP Mean SD
Group 1 CRP (mg/L) /T0
CRP (mg/L) /T1
CRP (mg/L) /T2
CRP (mg/L) /T3
CRP (mg/L) /T4
CRP (mg/L) /T5
10.229
10.682
12.582
19.853
24.190
45.500
5.4844
3.9480
6.0067
10.7765
11.5140
21.5873
Group 2 CRP (mg/L) /T0
CRP (mg/L) /T1
CRP (mg/L) /T2
CRP (mg/L) /T3
CRP (mg/L) /T4
CRP (mg/L) /T5
7.667
32.375
42.492
37.917
43.050
108.400
5.9344
61.0644
69.6184
52.8670
53.2230
33.4547
Group 3 CRP (mg/L) /T0
CRP (mg/L) /T1
CRP (mg/L) /T2
CRP (mg/L) /T3
CRP (mg/L) /T4
CRP (mg/L) /T5
6.308
14.338
19.354
30.815
49.190
115.377
6.5084
31.2970
30.4888
32.7972
37.9290
25.0041
TABLE 4
DIFFERENCE IN C-REACTIVE PROTEIN LEVEL
Sum of
Squares
df
Mean
Square
F Sig.
CRP /T0 Between
Groups
Within Groups
Total
119.687
1376.951
1496.638
2
39
41
59.844
35.306
1.695 0.197
CRP /T1 Between
Groups
Within Groups
Total
3564.286
53020.878
56585.164
2
39
41
1782.143
1359.510
1.311 0.281
CRP /T2 Between
Groups
Within Groups
Total
6574.790
65046.086
71620.876
2
39
41
3287.395
1667.848
1.971 0.153
CRP /T3 Between
Groups
Within Groups
Total
2404.532
45510.156
47914.688
2
39
41
1202.266
1166.927
1.030 0.366
CRP /T4 Between
Groups
Within Groups
Total
5157.901
50543.877
55701.778
2
39
41
2578.951
1295.997
1.990 0.150
CRP /T5 Between
Groups
Within Groups
Total
45090.397
27270.003
72360.400
2
39
41
22545.198
699.231
32.243 0.000
*P<0.05
creases in all groups, with highest level at 6 h (T3). These
elevations were significantly less pronounced in preoper-
ative clonidine group compared to levobupivacaine and
control group. It is known that IL-6 is proinflammatory
cytokine, his level is indicative for inflammatory re-
sponse in perioperative period, and it increases propor-
tionally to severity of inflammation. Our results are com-
parable to literature that investigate changes of IL-6 in
systemic inflammatory stress response and sepsis7,21,22,29,32.
In our study, CRP was significantly lower at the end of
investigation, compared to levobupivacaine and control
group (45.5 mg/L vs. 108.4 and 115.4 mg/L). Regarding
the literature, CRP is less sensitive marker for systemic
inflammatory stress response than cytokines and pro-
calcitonin23–27. Nevertheless persistent CRP elevation
over 100 mg/L is predictive for infectious postoperative
complications23.
Normally, leukocyte count increases in the postopera-
tive period as a result of inflammatory response to anes-
thesia and surgery. In the preoperative clonidine group,
we found leukocyte count within normal range compared
to other two groups. This contribute to clonidine effect
on inflammatory stress response blockade.
Conclusion
Using the centrally acting a2-adrenergic agonist clo-
nidine before the pain stimulus has set in resulted in
better systemic inflammatory stress response blockade
compared to levobupivacaine. From the clinical point of
view, this effect can contribute to faster postoperative re-
covery, which may be a worthwhile advantage to postop-
erative patients.
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TABLE 6
DIFFERENCE IN LEUKOCYTE LEVEL
Sum of Squares df
Mean
Square
F Sig.
leukocytes /T0 Between Groups
Within Groups
Total
1.725
79.191
80.916
2
39
41
0.862
2.031
0.425 0.657
leukocytes /T1 Between Groups
Within Groups
Total
38.309
589.615
627.924
2
39
41
19.155
15.118
1.267 0.293
leukocytes /T2 Between Groups
Within Groups
Total
282.993
836.799
1119.791
2
39
41
141.496
21.456
6.595 0.003
leukocytes /T3 Between Groups
Within Groups
Total
98.592
445.294
543.886
2
39
41
49.296
11.418
4.317 0.020
leukocytes /T4 Between Groups
Within Groups
Total
170.655
432.795
603.450
2
39
41
85.328
11.097
7.689 0.002
leukocytes /T5 Between Groups
Within Groups
Total
66.385
371.463
437.848
2
39
41
33.192
9.525
3.485 0.041
*P<0.05
TABLE 5
LEUKOCYTE LEVEL
GROUP Mean SD
Group 1 L (109/L) /T0
L (109/L) /T1
L (109/L) /T2
L (109/L) /T3
L (109/L) /T4
L (109/L) /T5
7.759
8.076
9.006
9.953
9.171
9.671
1.3224
3.2223
2.8800
2.9260
2.0551
2.6902
Group 2 L (109/L) /T0
L (109/L) /T1
L (109/L) /T2
L (109/L) /T3
L (109/L) /T4
L (109/L) /T5
7.344
8.317
10.142
11.875
12.675
11.100
1.0529
1.6118
2.9503
2.7496
3.1037
2.9505
Group 3 L (109/L) /T0
L (109/L) /T1
L (109/L) /T2
L (109/L) /T3
L (109/L) /T4
L (109/L) /T5
7.348
10.231
15.000
13.592
13.685
12.669
1.8031
5.7366
7.1200
4.3316
4.6481
3.6504
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PRIJEOPERACIJSKA PRIMJENA KLONIDINA ILI LEVOBUPIVAKAINA – U^INAK NA SUSTAVNI
UPALNI ODGOVOR ORGANIZMA
S A @ E T A K
Potpunom kontrolom perioperacijske boli mo`emo nadzirati odgovor imunosnog sustava i osloba|anje medijatora
upale, ~ime izravno utje~emo na ishod lije~enja. Primjena analgetika prije nastanka bolnog podra`aja (preventivna
analgezija) sprije~ava razvoj neuroplasti~nih promjena u sredi{njem `iv~anom sustavu, te mo`e smanjiti razinu boli.
Hipoteza istra`ivanja je da prijeoperacijska epiduralna primjena klonidina zna~ajno u~inkovitije blokira bol i sustavni
upalni odgovor organizma u odnosu na levobupivakain. Bolesnici su razvrstani u tri skupine, obzirom na prijeope-
racijsku epiduralnu primjenu klonidina, levobupivakaina ili fiziolo{ke otopine (kontrolna skupina). Prije operacije, 1 h
nakon po~etka operacije, te 1 h, 6 h, 12 h i 24 h nakon operacije analizirani su parametri: interleukin-6, C-reaktivni pro-
tein i leukociti. Izme|u ispitivanih skupina nije bilo statisti~ki zna~ajne razlike u dobi, spolu, tjelesnoj masi i trajanju
operacije. U skupini s klonidinom prije operacije dokazane su statisti~ki zna~ajno najni`e vrijednosti interleukina-6
tijekom cijelog vremena ispitivanja, u usporedbi s skupinom s levobupivakainom prije operacije i kontrolnom skupinom
ispitanika. Dokazane su zna~ajno najni`e vrijednosti C-reaktivnog proteina na kraju ispitivanja, u usporedbi s druge
dvije skupine ispitanika. Vrijednosti leukocita su tijekom cijelog vremena ispitivanja zna~ajno najni`e i unutar nor-
malnih granica jedino u skupini s klonidinom prije operacije. Istra`ivanjem su dokazane statisti~ki zna~ajne razlike,
koje potvr|uju va`nost centralnog u~inka klonidina na puteve boli i blokadu upalnog odgovora organizma.
J. Per{ec et al.: Preoperative Clonidine or Levobupivacaine, Coll. Antropol. 33 (2009) 2: 573–577
577
